Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C. M. Lau, Adrian G. Sacher, Shelley Kuang et al.|JTO Clinical and Research Reports|2021Cited by 11
P48.05 Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?Miguel García-Pardo, G. Liu, Sussane Schmid et al.|Journal of Thoracic Oncology|2021Cited by 3
Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium DataSabine Schmid, Ping Yang, Mei Jiang et al.|Cancer Epidemiology Biomarkers & Prevention|2022Cited by 2